Amneal Pharmaceuticals, Inc. AMRX Gain (Loss), Foreign Currency Transaction, before Tax
Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax?
- Amneal Pharmaceuticals, Inc. (AMRX) reported gain (loss), foreign currency transaction, before tax of -$7.8M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax decreased by 283.7% year-over-year, from $4.25M to -$7.8M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax?
- Over 3 years (2021 to 2024), Amneal Pharmaceuticals, Inc.'s gain (loss), foreign currency transaction, before tax has grown at a 168.2% compound annual growth rate (CAGR), from -$355K to -$6.85M.